Law Office of Brodsky & Smith, LLC Announces Investigation of BioForm Medical, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of BioForm Medical Inc. (“BioForm” or the “Company”) (Nasdaq:BFRM) related to the merger agreement with Merz Pharma Group.

Under the terms of the transaction, BioForm stockholders will receive $5.45 in cash pursuant to a cash tender offer followed by a second-step merger. The transaction is valued at approximately $253 million. The investigation concerns whether the board breached their fiduciary duties by agreeing to various deal protections that may prevent other superior offers. These protections include restrictions on solicitation of alternative proposals, a top-up option to acquire additional shares, the board’s agreement to pay a $8 million termination fee

If you are a BioForm shareholder and wish to discuss the legal ramifications of the Board’s actions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, 9595 Wilshire Blvd., Suite 900, Beverly Hills, CA 90212, by e-mail at clients@brodsky-smith.com, or by calling toll free 877-LEGAL-90.

Bioform Medical (MM) (NASDAQ:BFRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024